Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.

Leukemia & lymphoma ·Vol. 44 ·No. 4 ·2003-04-00 ·Pages 731-3

Paschal BR

Abstract

Denileukin diftitox (ONTAK) is indicated for the treatment of patients with cutaneous T cell lymphoma. Clinical experience with this drug in other lymphomas is limited. This case report concern a patient with stage IV follicular lymphoma who, relapsing after autologous transplant and having failed multiply systemic therapies, including retuximab and CHOP, achieved a prolonged remission with denileukin diftitox.

MeSH Terms

Adult Antibodies, Monoclonal/therapeutic use Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents/therapeutic use Antineoplastic Combined Chemotherapy Protocols/therapeutic use Cyclophosphamide/therapeutic use Diphtheria Toxin/therapeutic use Disease Progression Doxorubicin/therapeutic use Humans Interleukin-2/therapeutic use Lymphoma, Non-Hodgkin/drug therapy,therapy Male Peripheral Blood Stem Cell Transplantation/methods Prednisone/therapeutic use Recombinant Fusion Proteins/therapeutic use Remission Induction Rituximab Time Factors Vidarabine/analogs & derivatives,therapeutic use Vincristine/therapeutic use

Chemicals

Antibodies, Monoclonal Antibodies, Monoclonal, Murine-Derived Antineoplastic Agents Diphtheria Toxin Interleukin-2 Recombinant Fusion Proteins denileukin diftitox Rituximab Vincristine Doxorubicin Cyclophosphamide Vidarabine fludarabine Prednisone

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Paschal Barton R

Asheville Hematology & Oncology Associates, PA., One Doctors Drive, Asheville, NC 28801, USA.

Supplementary Concepts

CHOP protocol (Protocol)

Article Info

Journal

Leukemia & lymphoma

Abbr.

Leuk Lymphoma

ISSN

1042-8194

DOI

10.1080/1042819031000063854

Published

2003-04-00

Pages

731-3

Language

English

Region

United States

NLM ID

9007422

Subset

External Links

PubMed source DOI: 10.1080/1042819031000063854 View journal details

Analysis Services

Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.

Contact

WeChat Official Account